These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23341582)

  • 21. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register.
    Soliman MM; Hyrich KL; Lunt M; Watson KD; Symmons DP; Ashcroft DM;
    Arthritis Care Res (Hoboken); 2012 Aug; 64(8):1108-15. PubMed ID: 22422731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
    Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study.
    Gomez-Reino JJ; Maneiro JR; Ruiz J; Roselló R; Sanmarti R; Romero AB;
    Ann Rheum Dis; 2012 Nov; 71(11):1861-4. PubMed ID: 22736086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
    Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
    Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myocardial infarction after rituximab treatment for rheumatoid arthritis: Is there a link?
    van Sijl AM; van der Weele W; Nurmohamed MT
    Curr Pharm Des; 2014; 20(4):496-9. PubMed ID: 23565629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab.
    Abdulkader R; Dharmapalaiah C; Rose G; Shand LM; Clunie GP; Watts RA
    J Rheumatol; 2014 May; 41(5):858-61. PubMed ID: 24634201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment.
    Magnusson M; Brisslert M; Zendjanchi K; Lindh M; Bokarewa MI
    Rheumatology (Oxford); 2010 Oct; 49(10):1911-9. PubMed ID: 20547657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital.
    Couderc M; Mathieu S; Pereira B; Glace B; Soubrier M
    Arthritis Care Res (Hoboken); 2013 Apr; 65(4):648-52. PubMed ID: 23045227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study.
    Keystone EC; Cohen SB; Emery P; Kremer JM; Dougados M; Loveless JE; Chung C; Wong P; Lehane PB; Tyrrell H
    J Rheumatol; 2012 Dec; 39(12):2238-46. PubMed ID: 23027887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis.
    Lin KM; Lin JC; Tseng WY; Cheng TT
    J Microbiol Immunol Infect; 2013 Feb; 46(1):65-7. PubMed ID: 22627098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry.
    Payet S; Soubrier M; Perrodeau E; Bardin T; Cantagrel A; Combe B; Dougados M; Flipo RM; Le Loët X; Shaeverbeke T; Ravaud P; Gottenberg JE; Mariette X
    Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1289-95. PubMed ID: 25299001
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of rituximab in combination with other biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: an open-label study.
    Rigby WF; Mease PJ; Olech E; Ashby M; Tole S
    J Rheumatol; 2013 May; 40(5):599-604. PubMed ID: 23547218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induced psoriasis after rituximab therapy for rheumatoid arthritis: a case report and review of the literature.
    Guidelli GM; Fioravanti A; Rubegni P; Feci L
    Rheumatol Int; 2013 Nov; 33(11):2927-30. PubMed ID: 23135613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Safety of rituximab in patients with rheumatoid arthritis].
    Morović-Vergles J
    Reumatizam; 2010; 57(2):158-60. PubMed ID: 21875022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term real-life experience with rituximab in adult Finnish patients with rheumatoid arthritis refractory or with contraindication to anti-tumor necrosis factor drugs.
    Valleala H; Korpela M; Hienonen-Kempas T; Immonen K; Lähteenmäki J; Uusitalo T; Komulainen R; Möttönen T; Hannonen P
    J Clin Rheumatol; 2015 Jan; 21(1):24-30. PubMed ID: 25539430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy in Poland].
    Samborski W; Buczek J; Bednarek A; Lewandowicz J; Kucharz E
    Pol Merkur Lekarski; 2010 Dec; 29(174):365-8. PubMed ID: 21298986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries.
    Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PL; Nordström DC; Gomez-Reino J; Pavelka K; Tomsic M; Kvien TK; van Vollenhoven RF
    Ann Rheum Dis; 2011 Sep; 70(9):1575-80. PubMed ID: 21571731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Development of psoriasis in a patient with reumatoid arthritis after rituximab].
    Feced Olmos CM; Ivorra Cortés J; Alegre Sancho JJ; Roman Ivorra JA
    Med Clin (Barc); 2014 Jan; 142(1):40-1. PubMed ID: 23510613
    [No Abstract]   [Full Text] [Related]  

  • 39. Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis.
    Fabris M; Quartuccio L; Lombardi S; Benucci M; Manfredi M; Saracco M; Atzeni F; Morassi P; Cimmino MA; Pontarini E; Fabro C; Pellerito R; Sarzi-Puttini P; Cutolo M; Carletto A; Bambara LM; Fischetti F; Curcio F; Tonutti E; De Vita S
    Reumatismo; 2010; 62(4):253-8. PubMed ID: 21253618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Optimizing rheumatoid arthritis treatment with rituximab--individualized patient approach].
    Novak S
    Reumatizam; 2010; 57(2):156-7. PubMed ID: 21875021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.